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Abstract  
Hepatocellular carcinoma is rarely associated with pregnancy and when it does there is poor prognosis for both the mother and the baby.There is 
paucity of evidence for best practice in hepatocellular carcinoma in pregnancy especially in the background of cirrhosis and decompensation. We 
present a 36 year old gravida 5 para 4 at 27 weeks gestation with hepatocellular carcinoma and main complaint of abdominal pain. She had 
chronic hepatitis B infection with hepatocellular carcinoma on a cirrhotic background. There were both clinical and laboratory features suggestive 
of liver decompensation. The pregnancy outcome was a fresh stillbirth with mother alive. This case report highlights the management dilemma of 
hepatocellular carcinoma in pregnancy on the background of decompensated liver cirrhosis and chronic hepatitis B infection. 
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Hepatocellular cancer(HCC) is the commonest cause of all primary 
liver cell cancers worldwide [1]. In Sub-Saharan Africa and eastern 
Asia chronic hepatitis B infection has been implicated as the major 
aetiologic factor. Other aetiologic factors include alcohol abuse, 
chronic hepatitis C and aflatoxin which have all been linked to Liver 
Cirrhosis [1,2]. Primary liver cancer in pregnancy is rare with very 
poor prognosis. Studies have reported the maternal and fetal losses 
as almost 100% in many case reports and series [3]. However, a 
distinct histological subtype referred to as fibrolamellar HCC 
(FLHCC) is associated with a better prognosis and usually in a non-
cirrhotic liver [4]. There are no clear guidelines on the management 
of HCC in pregnancy especially on a cirrhotic background with 
decompensation and in the presence of e-Antigen positive chronic 
hepatitis B infection. The current WHO guidelines (March 2015) 
recommends Tenofovir an antiviral as safe and efficacious in 
pregnancy for chronic hepatitis B infection but did not discuss 
options for the triad of pregnancy, HCC and chronic hepatitis B 
infection [5]. We present a case of hepatocellular carcinoma (HCC) 
in the third trimester of pregnancy with underlying chronic hepatitis 
B infection and liver decompensation. The management dilemma 
and outcome of HCC in pregnancy in our client were highlighted. 
  
  
Patient and observation 
 
A 36 year old female farmer gravida 5 para 4 at 27 weeks gestation 
presented to our facility. Her main complaint was a 3 month history 
of epigastric abdominal pain, which was gradual in onset, dull and 
persistent. Pain had gradually worsened over the months with no 
known relieving or aggravating factors but with intermittent 
radiation to the chest. There was a history of significant weight loss 
but no associated early satiety, jaundice, fever, itch or spontaneous 
bleeding. No history of blood transfusion and patient was on her 
routine hematinic from the antenatal clinic (ANC). She is not a 
known diabetic, Hypertensive and has no known chronic illness. 
Patient did not know her Hepatitis status. Denied to taking any 
alcohol or smoking. There were no cardiorespiratory nor urogenital 
symptoms. She did not store grains at home and had no known 
contact with chemicals or ionizing radiation. Clinical signs on 
examination included wasting, mild pallor, a tinge of jaundice but 
well hydrated, afebrile and no palpable lymphnodes. She had 
palmer erythema but no clubbing and parotid enlargement. 
Respiratory, cardiovascular and neurological examinations were 
unremarkable. Abdomen was grossly distended with distorted 
contour in the upper half and visibly distended anterior abdominal 
wall veins draining away from the umbilicus. Liver was enlarged 
12cm below the costal margin with a span of 17cm. The liver was 
hard, nodular with irregular edge, mild tendernes and had a bruit on 
auscultation. The spleen was not palpable but with demonstrable 
mild ascites and bipedal eodema up to the mid shin. Symphysio 
fundal height was 26 cm, with longitudinal lie and breech 
presentation. Fetal heart rate was 134bpm and regular.Rectal and 
vaginal examination were unremarkable. Initial diagnosis of 
hepatocellular Carcinoma in pregnancy was made. 
  
Laboratory assessment revealed HB-10.3g/dl, WBC 10200 cells/dl; 
Neutrophils 59.3%, lymphocytes 26.1%, Monocytes 10.1% and 
Eosinophils 2.7%. Platelets 350000/ul. Normal bilirubin but GGT and 
AST were raised (4times upper limit). Total protein and albumin 
were low, 44g/L and 29g/L respectively with INR-1.3.HBsAg was 
positive, HBeAg negative with HBV DNA level of 126869 IU/ml(Viral 
load). VDRL positive but TPHA not done. Alphafeto protein (AFP) 
>50000KU/L. She tested negative to HIV and HCV. Abdominal 
ultrasound showed a heterogeneous coarse liver with multiple 
hypoechoic lesions. The liver measured 17.2cm and there was mild 
ascites. Pelvic scan revealed a 27 week, 3 day old fetus, with active 
fetal movements. A revised diagnosis of hepatocellular carcinoma on 
a cirrhotic liver with decompensation in pregnancy was made. She 
was managed with analgesia, furosemide, spironolactone and 
lamivudine added for prevention of mother to child transmission of 
the hepatitis B infection. The plan was to allow pregnancy to 
continue to at least 32 completed weeks to improve the chance of 
neonatal survival. However because of the progressive unbearable 
abdominal pain, pregnancy was terminated at 30 weeks 3days by 
successful induction of labour. The outcome was a fresh stillbirth 
weight 1.2kg. Pain was markedly reduced post-delivery and was 
discharged home after 5days. She was booked for a follow up visit 
at the gastrointestinal clinic. She was seen at the clinic at 2 weeks 
and four weeks post discharge but was lost to follow up afterwards 





Hepatocellular carcinoma is rarely associated with pregnancy and its 
occurrence together has a poor prognosis for both the mother and 
the baby [6,7]. Our patient presented in the third trimester with 
features suggestive of hepatocellular carcinoma (large nodular liver 
with a bruit and significant weight loss). The diagnosis was 
confirmed with abdominal ultrasound and markely elevated alpha 
fetoprotein (AFP) ie > 50,000 KU/L bearing in mind that AFP is also 
raised in pregnancy and flare of chronic hepatitis B infection. The 
AFP value obtained for this patient is extremely high and usually 
seen in clients with HCC. The pregnancy and a possile flare of 
hepatitis B infection cannot explain the high AFP value in our client. 
She did not know her hepatitis B status but the results from our 
laboratory showed that she had e-antigen negative chronic hepatitis 
B with HBV DNA level of 126869 IU/ml. This clinical picture suggests 
a possible pre-core or core promoter mutation in our client as 
usually e-antigen negative patients are in the immune control phase 
with very low viral loads. Our client also had features of liver 
decompensation and the ultrasound rightly described HCC on a 
cirrhotic background. Oestrogen is known to stimulate hepatic 
growth, alter liver metabolism, and endogenous hormones may 
contribute to the rapid growth of liver cancer during pregnancy in 
the context of our client [8]. With the cirrhotic background in her 
case it may be that she had the HCC before the pregnancy but was 
small in size which the pregnancy factors catalysed its growth to a 
symptomatic phase. There is a remarkable increase in oestrogen 
levels during pregnancy. Our client engaged in active farming during 
pregnancy and with the evidence that aerobic exercise can affect 
the hypothalamic-pituitary-gonadal axis, this may lead to a 
reduction in oestrogen and progestogens from the ovaries [9]. This 
may explain why our client only reported in the last trimester since 
the early phase had less symptoms. We could not assay the 
hormone level to confirm this as she only reported to us in the last 
trimester for the first time. 
  
There should be a careful evaluation of all pregnant women 
especially when abnormal masses are seen in the liver on abdominal 
sonography. Further investigations with magnetic resonance 
imaging (MRI), Triphasic Computerised tomography together with 
maternal serum AFP and amniotic fluid AFP if the facilities are 
available will help identify pregnant women with liver cancer for 
early optimal management of the mother and baby. In the case of 
HCC with pregnancy and chronic hepatitis B infection there are no 
clear guidelines. The current WHO guidelines indicates that 
Page number not for citation purposes 3
treatment in adults with chronic hepatitis B also apply to pregnant 
women. Tenofovir and or lamivudine or emtricitabine is 
recommended as it has a better resistance profile and more 
extensive safety data in pregnant HBV positive mothers [5,10]. The 
guideline did not make a recommendation on the use of antivirals 
for preventing mother to child transmission as trials are on-going 
but recommends first dose vaccine within 24 hour of delivery [10]. 
The decision to terminate a pregnancy in this context at any point in 
time may be a call by the doctor but decision purely rest on the 
clients consent. Regular follow up during and after delivery is 





Management of chronic hepatitis B infection complicated by 
hepatocellular carcinoma in pregnancy poses a treatment dilemma 
as the continuance of the pregnancy accelerates disease 
progression. Clinicians should add to the body of knowledge to help 
develop evidence based guidelines to improve maternal and fetal 
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Figure 1: Showing massive hepatomegaly with distended veins and 
the pregnancy  
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Figure 2: Fetal head and the hepatomegaly with HCC in ultrasound view 
 
 
 
 
 
 
